848 related articles for article (PubMed ID: 27847296)
41. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
[TBL] [Abstract][Full Text] [Related]
42. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
43. Obesity and long-term survival after radical prostatectomy.
Chalfin HJ; Lee SB; Jeong BC; Freedland SJ; Alai H; Feng Z; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
J Urol; 2014 Oct; 192(4):1100-4. PubMed ID: 24769031
[TBL] [Abstract][Full Text] [Related]
44. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
[TBL] [Abstract][Full Text] [Related]
45. Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling.
Ginsburg K; Cole AI; Silverman ME; Livingstone J; Smith DW; Heilbrun LK; Shi D; Mehra R; Sakr WA; Morgan TM; Cher ML
Urol Oncol; 2020 Mar; 38(3):78.e1-78.e6. PubMed ID: 31791703
[TBL] [Abstract][Full Text] [Related]
46. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
48. [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?].
Meunier ME; Neuzillet Y; Radulescu C; Cherbonnier C; Hervé JM; Rouanne M; Molinié V; Lebret T
Prog Urol; 2018 Sep; 28(10):475-481. PubMed ID: 29907495
[TBL] [Abstract][Full Text] [Related]
49. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
[TBL] [Abstract][Full Text] [Related]
50. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.
Freedland SJ; deGregorio F; Sacoolidge JC; Elshimali YI; Csathy GS; Dorey F; Reiter RE; Aronson WJ
J Urol; 2003 Apr; 169(4):1325-30. PubMed ID: 12629353
[TBL] [Abstract][Full Text] [Related]
51. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.
Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG
BJU Int; 2017 Nov; 120(5):651-658. PubMed ID: 28371244
[TBL] [Abstract][Full Text] [Related]
52. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
Ellis CL; Partin AW; Han M; Epstein JI
J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
[TBL] [Abstract][Full Text] [Related]
53. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
54. A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
Lu J; Wirth GJ; Wu S; Chen J; Dahl DM; Olumi AF; Young RH; McDougal WS; Wu CL
J Urol; 2012 Jul; 188(1):91-7. PubMed ID: 22578729
[TBL] [Abstract][Full Text] [Related]
55. Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer.
Sved PD; Gomez P; Manoharan M; Kim SS; Soloway MS
J Urol; 2004 Jul; 172(1):98-102. PubMed ID: 15201746
[TBL] [Abstract][Full Text] [Related]
56. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
57. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
58. Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
Murata Y; Tatsugami K; Yoshikawa M; Hamaguchi M; Yamada S; Hayakawa Y; Ueda K; Momosaki S; Sakamoto N
Int J Urol; 2018 Mar; 25(3):284-289. PubMed ID: 29315854
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
Kır G; Seneldir H; Gumus E
Ann Diagn Pathol; 2016 Feb; 20():48-51. PubMed ID: 26750655
[TBL] [Abstract][Full Text] [Related]
60. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
